BriaCell Therapeutics (BriaCell Therapeutics) EBITDA Margin % : 0.00% (As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BriaCell Therapeutics's EBITDA for the three months ended in Jan. 2024 was $-9.83 Mil. BriaCell Therapeutics's Revenue for the three months ended in Jan. 2024 was $0.00 Mil. Therefore, BriaCell Therapeutics's EBITDA margin for the quarter that ended in Jan. 2024 was 0.00%.

BriaCell Therapeutics EBITDA Margin % Historical Data

The historical data trend for BriaCell Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics EBITDA Margin % Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

EBITDA Margin %

Get a 7-Day Free Trial

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BriaCell Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, BriaCell Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's EBITDA Margin % falls into.

BriaCell Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BriaCell Therapeutics's EBITDA Margin % for the fiscal year that ended in Jul. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jul. 2023 )	/	Revenue (A: Jul. 2023 )
	=	-20.287	/	0
	=	%

BriaCell Therapeutics's EBITDA Margin % for the quarter that ended in Jan. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-9.826	/	0
	=	%

BriaCell Therapeutics (NAS:BCTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

BriaCell Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

BCT:Canada

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Executives

Jamieson Bondarenko	director	402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub	director	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin	officer: CFO & Secretary	MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del	officer: Chief Medical Officer	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams	director, officer: President & CEO	620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg	director	201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago	officer: Chief Scientific Officer	2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony	director	P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig	director	4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3